Title: Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile

Author List: Vatsalya Vatsalya, MD, MS, PgD, MSc^{1,2*}, Fengyuan Li, PhD^{1,3}, Jane Frimodig, PhD^{1,2}, Khushboo S. Gala, MD¹, Shweta Srivastava, PhD^{1,4}, Maiying Kong, PhD^{2,5}, Vijay A Ramchandani, PhD⁶, Wenke Feng, PhD^{1,3,7,10}, Xiang Zhang, PhD^{3,7,8,9,10}, Craig J McClain, MD^{1,2,3,7,10}

Affiliations:

¹Department of Medicine, University of Louisville, Louisville, KY USA

²Robley Rex VA Medical Center, Louisville, KY USA

³University of Louisville Alcohol Research Center, Louisville, KY USA

⁴Envirome Institute, University of Louisville, Louisville, KY USA

⁵Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY USA

⁶National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD USA

⁷Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY USA

⁸Department of Chemistry, University of Louisville, Louisville, KY USA

⁹Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY USA

¹⁰University of Louisville Hepatobiology & Toxicology COBRE, Louisville, KY USA

***Corresponding Author:**

Vatsalya Vatsalya, MD, MS, PgD, MSc

Department of Medicine

University of Louisville School of Medicine

505 S. Hancock St., CTR Room 514A

Louisville KY 40202

Landline: 502-852-8928, Fax: 502-852-8927

Cell: 502-488-0446; Email: v0vats01@louisville.edu

Running Head: Thiamine Treatment for COVID-19: Th17 Immune Storm and Neurological Symptoms.

Author contribution: VV is the project PI and designed the study. VV and JF participated in the clinical sampling and clinical data analyses. FL performed *in vitro*, and JF performed plasma testing. FL, JF, and VV participated in the overall laboratory analyses. MK and VV developed the dosing range. VV, CJM and VAR developed the pharmacokinetic profile. VV, FL, SS, and JF interpreted the results. VV, FL, JF, SS, and KSG wrote the manuscript. CJM, MK, WF, XZ, and VAR critically reviewed the manuscript and contributed scientifically. All authors have approved the submission version of this manuscript.

Conflicts of Interest: All authors declare no conflict of interests.

Proprietorship: This article is a work of the University of Louisville Alcohol Research Center and National Institutes of Health. This manuscript is in the public domain in the USA. Email address for the readers to contact the author to obtain the data: v0vats01@louisville.edu.

Project/Grant Support: Study was supported by NIH: NIH-OD-OHSRP-12176 (VV), R15CA170091-01A1 (MK), ZIA AA000466 (VAR), R01AA023190 (WF), P50AA024337-8301 and P20GM113226-6169 (XZ), and P50AA024337, P20GM113226, U01AA026936, U01AA0279880, R01AA023681 (CJM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgments: We thank research/clinical staff of the University of Louisville for their support. We thank Ms. Marion McClain for editing this manuscript.

Ethics approval and consent to participate: Study was approved by the sites' Institutional Review Boards (Ethics committees). All patients included in this study consented to participate before the beginning of the study.

Availability of data and materials: The datasets analyzed during the current study are available from the corresponding author by request.

Disclosure: This article is not published nor is under consideration for publication elsewhere at the time of submission.

Abbreviations: COVID-19: Coronavirus Disease-19, IL-17: Interleukin 17, IL-22: Interleukin 22, Disease Controls: (DC), HV: Healthy Volunteers.

Trial registration: ClinicalTrials.gov identifier - NCT# 01809132 and 00106106.

Reprint requests: Vatsalya Vatsalya MD, PgD, MSc, MS, Department of Medicine, University of Louisville School of Medicine, 505 S. Hancock St., CTR Room 514A, Louisville KY 40202 USA. Tel.: 502-852-8928. Fax: 502-852-8927. E-mail: v0vats01@louisville.edu.

Manuscript metadata:

Word Count in manuscript draft: 3383 manuscript words.

Tables and Figures: 1 Table, 4 Figures, and 2 Suppl. Tables.

Number of References: 110.

Abstract

Introduction

Emerging infectious diseases, especially the coronavirus disease identified in 2019 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17 proinflammatory immune storm. This enhanced immune response plays a major role in mortality and morbidity, including neurological symptoms. We hypothesized that countering the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell proinflammatory response. We used an *in vitro* study and corroborated those results in disease controls (DC). We developed an effective dose range and model for key pharmacokinetic measures with the potential of targeting the cytokine storm and neurological symptoms of COVID-19.

Study Participants and Methods

We investigated the effect of a three-week 200 mg dose of thiamine in lowering the Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients; and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To further investigate, we performed an *in vitro* study evaluating the effectiveness of thiamine treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line (RAW264.7) treated with ethanol. In this *in vitro* study, 100 mg/day equivalent (0.01 µg/ml) thiamine was used. Based on recent publications, we compared the results of the IL-17 response from our clinical and *in vitro* study to those found in other proinflammatory disease conditions (metabolic conditions, septic shock, viral infections and COVID-19), including symptoms, and dose ranges of effective and safe administration of thiamine. We developed a

dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-19 to alleviate the effects of the cytokine storm and neurological symptoms.

Results

The DC group showed significantly elevated proinflammatory cytokines compared to HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an *in vitro* macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in other viral infections and neuroinflammatory states that may also respond to thiamine treatment.

Discussion

The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in severe COVID-19 patients could identify its precise anti-inflammatory role.

Key words: COVID-19, IL-17, IL-22, Cytokine storm, Pandemic

Introduction

Viral diseases and wide-spread outbreaks have adverse health-related consequences worldwide. Emerging infectious diseases (EID) include viral pathogens that have shown higher incidence of human infection in the past several decades and raise concerns regarding increased ongoing/future prevalence ¹. Coronavirus is recognized as an EID that has become a challenging and aggressive infection with high morbidity and mortality in humans ². SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; causes coronavirus disease [COVID-19]) was identified in 2019, has become a pandemic, and is a priority healthcare concern in the year 2020 ³.

In viral infections, tissue inflammation is driven by multiple proinflammatory and immunoregulatory signals ^{4,5}. The pathological progression of COVID-19 has multiple clinical stages and may present with the cytokine storm syndrome ⁶ and immunosuppression ⁷. Interleukin-17 (IL-17) is a cytokine ⁸ that is often involved in a proinflammatory response in the cytokine storm of viral infections ⁹⁻¹¹. It can also promote respiratory viral infections ¹², tissue pathology ¹³⁻¹⁵, and neurological manifestations ¹⁶. Th17 cells also produce Interleukin-22 (IL-22), which plays a protective/anti-inflammatory role, and it is dysregulated in several proinflammatory conditions ¹⁷. Thus, a therapy that could alleviate the Th17 mediated pro-inflammatory response ¹⁸ might be effective in attenuating the cytokine storm observed in COVID-19 patients.

Thiamine, a vitamin and dietary supplement, ¹⁹ has anti-oxidant properties ^{19,20}. High levels of cytokines (for example, IL-1 β and IL-6) may occur in thiamine deficient subjects and can be associated with oxidative stress and inflammation ^{21,22}. Importantly, thiamine

administration could inhibit production of these cytokines, increase anti-inflammatory activity^{23,24}, and potentially alleviate neuroinflammatory symptoms of viral origin^{25,26}.

We tested the efficacy of a three-week thiamine treatment in modulating the Th17 proinflammatory response in a human disease control model of conditions associated with inflammation. To validate the effectiveness of thiamine in treating the proinflammatory response from the human study, we conducted an *in vitro* experiment to test the effects of thiamine treatment in alleviating ethanol mediated immune dysregulation in a mouse macrophage cell line, RAW264.7. We investigated the Th17 cells proinflammatory cytokine response (namely IL-17) in both healthy controls and individuals with high inflammatory response. This was done to estimate the effects of various doses of thiamine that have shown efficacy in alleviating the Th17 associated cytokine response. We assessed the pharmacokinetics of the oral thiamine dosing. Lastly, we also examined the neurological symptoms of COVID-19 that could possibly be treated with thiamine.

Study Participants and Methods

Study Participants

This investigation was approved under two large clinical investigations that were conducted at the University of Louisville (NCT#01809132, HV cohort), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NCT#00106106, DC cohort) at the National Institutes of Health (NIH), Bethesda MD. The studies were approved by the NIH Institutional Review Board (IRB) committee and the UofL IRB (IRB # 12.0427). All DC (disease controls as termed in this study, who were alcohol use disorder [AUD]) patients received acamprosate (or placebo) as

part of a larger addiction intervention investigation. All of these patients also received thiamine as part of the medical management, which is the primary aim of this study. Sixteen age- and sex- matched male and female alcohol use disorder (AUD) patients (Termed as disease controls [DC] in this investigation) between 21-65 yrs. of age with both present and past heavy drinking profile participated as the DC, who were diagnosed with AUD based on DSM-IV TR criteria. They received daily doses of open label thiamine (100 mg twice daily = 200 mg per day)²⁷ for 3-weeks after completion of the consenting process. DC patients also received standard of care inpatient medical management, including counseling. Detailed information on subject recruitment and management can be obtained from several of our previous publications²⁸⁻³¹. We also included eight healthy controls in this study for comparison with DC. Demographic data were collected from all the participants. Baseline (HV and DC) and post-treatment (DC only) blood samples (after the completion of 3-weeks of thiamine dosing) were collected, processed (for plasma extraction) and frozen at -80°C. They were subsequently thawed and assayed.

Laboratory Assays and Therapeutic Model on Th17 Inflammation Axis

(1) Cytokine assays

Plasma levels of proinflammatory cytokines, IL-1 β , IL-6, and IL-10 were obtained by multianalyte chemiluminescent detection using Multiplex kits (Millipore, Billerica, MA) on the Luminex platform (Luminex, Austin, TX), according to manufacturers' instructions.

(2) Analysis of IL-17 and IL-22 in a set of AUD patients for designing proof-of-concept experimental model

We performed analyses for IL-17 and IL-22 on human plasma samples to estimate the Th17 inflammatory response, with the goal of developing an *in vitro* mechanistic experimental

model to test the efficacy of thiamine. The plasma levels of IL-17 and IL-22 in eight healthy volunteers were also included in this study for comparison. IL-17 and IL-22 were detected in plasma using Human IL-17A (now called IL-17) High Sensitivity ELISA Kits (BMS2017HS, Invitrogen) and Human IL-22 ELISA Kits (BMS2047, Invitrogen) per the manufacturer's instructions. Results were read on a Spectra Max Plus 384 plate reader and modeled using their SoftMax Pro software (Molecular Devices, San Jose, CA).

(3) Cell culture

RAW 264.7 cells (mouse macrophage cell line) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were seeded in a 24-well culture plate and maintained at 37 °C in a 5% CO₂ incubator for 3 days. The 0.02 µg/mL treatment dose was equivalent to the 200 mg/day thiamine dose (approximate blood AUC = 204 nmol/L³²) given to the patients. Cells were then treated with thiamine (Vit B1 [V_{B1}]) as shown in the Figure 2) at a concentration of (0.01 µg/mL) for 2 hours (in a preventive paradigm), followed by 80 mM ethanol treatment for 22 hours, for a total of 24 hours of treatment to determine the minimum effective level of thiamine to reduce the Th17 response. Cells were then washed with PBS and collected with Trizol reagent for the isolation of RNA. RNA samples were reverse transcribed to cDNA and used for qRT PCR analysis of cytokine expression (IL-17, IL-22). Cell viability was not affected by thiamine or EtOH treatment at the doses used in the experiments.

(4) RNA isolation and real-time RT-PCR

Total RNA was extracted from the cells using Trizol reagent (500 µl/well) according to manufacturer's instruction (Life Technologies, Carlsbad, CA) and reverse-transcribed using

cDNA Supermix (QuantaBio, Beverly, MA). Quantitative real-time PCR was performed on an ABI 7500 real-time PCR thermocycler and SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA) was used for quantitative real-time PCR analysis. The relative quantities of target transcripts were calculated from duplicate samples after normalization of the data against the housekeeping gene, mouse 18S. Relative mRNA expression was calculated using comparative Ct method. The following primer pairs were used:

Gene name	Forward sequence 5'→3'	Reverse sequence 5'→3'
ms <i>IL-17</i>	ATCCCTCAAAGCTCAGCGTGTC	GGGTCTTCATTGCGGTGGAGAG
ms <i>IL-22</i>	GTCAACCGCACCTTTATGCT	CATGTAGGGCTGGAACCTGT
ms <i>18S</i>	GTAACCCGTTGAACCCCAT	CCATCCAATCGGTAGTAGCG

Development of the Pharmacokinetic Model for Dose Titration of Thiamine

We used dosing guidelines for thiamine as mentioned at the Medline Plus (<https://medlineplus.gov/druginfo/natural/965.html#Safety>, last reviewed as of August 5, 2020), and from peer reviewed publications from PubMed (<https://pubmed.ncbi.nlm.nih.gov/>; [searched and collected until August 5, 2020]). We used available dosing guidelines from Medline Plus for healthy individuals both for dietary supplementation and vitamin deficiency status. We also reviewed and incorporated thiamine dose levels (lower and higher range) from other disease conditions; namely metabolic conditions^{33,34}, septic shock^{35,36}, viral diseases³⁷⁻³⁹ and Leigh's disease⁴⁰ ([Medline Plus: Thiamine](#)). We also included the recorded thiamine dose levels from the DC group (AUD with Wernicke Korsakoff Syndrome, WKS⁴¹; from our clinical study) as one of the pro-inflammatory conditions.

We compared the reference range of levels of the Th17 cytokine (IL-17) response in disease/health conditions in humans as published in the recent findings concerning COVID-19's cytokine storm data⁴²⁻⁴⁴. A Th17 proinflammatory response for the potential range of IL-17 levels was also developed for healthy volunteers (HV, from our study cohort), metabolic conditions^{45,46}, DC (or alcohol use disorder patients from our study cohort), septic shock^{47,48}, and viral infections^{12,49}. IL-17 data on severe COVID-19 patients (as mentioned above) were collected from the recently peer-reviewed published articles found in PubMed (searched until August 5, 2020). Doses administered to our DC study cohort, and data from healthy individuals (HV) were also used in the development of the dose profile. All these data were incorporated in the predictive regression model for identifying a tentative effective dose range of thiamine (Figure 3).

The pharmacokinetic response of thiamine was calculated at both the low and high ends of the dose range described above. The area under the curve and maximum concentration (C_{max}) were established for both blood and plasma for a 10-hour trajectory (Figure 4) using the indices of thiamine's *in vivo* blood pharmacokinetics³². For the derived 79 mg thiamine dosing (low end), the slopes used to identify AUC in blood were 2.14, and 1.76 in plasma. For the 474 mg thiamine dosing (upper end), the slope used to derive AUC in blood was 1.02, while in plasma it was 1.09. Similarly, for the 79 mg thiamine dosing, the slope used to derive C_{max} in blood was 0.40, and in plasma it was 0.39. For the 474 mg thiamine dose, the slope used to derive AUC in blood was 0.14, and in plasma it was 0.18.

Statistical Analysis

Data are expressed as Mean $\pm$ standard deviation (M $\pm$ SD) in Table 1 as well as in Figures 1 and 2. Two-sided Student's t-test was used to examine the difference between disease controls and healthy volunteers at baseline (see Suppl. Table 1 and Fig. 1), and two-sided Student's paired t-test was used to examine the changes at baseline versus 3 weeks for disease controls (Figure 1).

Post-hoc one-sided t-tests were performed for the IL-17 and IL-22 mRNA expression analyses for the RAW 264.7 cells testing (Figure 2). A pharmacokinetic model for anticipated therapeutic dosing range of thiamine based on IL-17 ranges in different inflammatory conditions was constructed using predictive regression computation (Figure 3). Factorial between-group ANOVA was used to evaluate demographic and cytokine profiles (Table 1). Statistical significance was established at $p < 0.05$. SPSS 26.0 (IBM Chicago, IL) and Microsoft Excel 365 (MS Corp, Redmond WA), statistical software R (<https://www.r-project.org/>), and Prism GraphPad (GraphPad Software, San Diego CA) were used for statistical analysis, data computation, and plotting the figures.

Neurological Assessments

We conducted a review on the neurological presentation in COVID-19 and other relevant viral occurrences of encephalitis (Table 1). We identified and tabulated the neurological symptoms of COVID-19 and viral encephalitis from the recently published findings. We also described the neurological symptoms, that are generally treated effectively with thiamine (Table 1). We used PubMed and Medline Plus for disease references (searched until August 5, 2020).

Results

Demographics and Candidate Proinflammatory Cytokine Profile

DC group individuals in this study had significantly higher age than the healthy controls (HV) (Suppl Table 1). However, there was no significant difference in the mean BMIs between the two groups, and the sex-distribution was also similar between the two groups. Both IL-6 (~6 fold) and IL-1 β (~3 fold) cytokines were significantly higher in the DC group (AUD patients) compared to the healthy controls/volunteers (HV) group. IL-10 was also numerically higher in the DC group.

Clinical Findings on the Immune Response of Th17 derived IL-17 and IL-22 Axis Response, and Thiamine Efficacy and Safety

To develop a model for thiamine effects on inflammation, we assessed IL-17 and IL-22 cytokine expression (showing proinflammatory and anti-inflammatory effects, respectively). Both cytokines are produced by the Th17 cells⁵⁰. IL-17 concentrations were below the level of detection in the HV group, but were elevated in the DC group. An approximate four-fold decrease was observed in the IL-17 concentration levels (0.09 pg/mL to 0.023 pg/mL) with a treatment dose of 200 mg thiamine daily (Estimated AUC = 204 nmol/L x hour approximately in the 10-hr. window) by the end of week 3. IL-22 was significantly decreased in DC group compared to healthy volunteers and thiamine therapy did not significantly improve levels in treated DC group individuals. No patients reported any kind of drug related adverse events; therefore, the safety profile of thiamine administration was excellent at 200 mg daily in this small pilot group.

Experimental Model for Treatment Efficacy of Thiamine on IL-17 and IL-22 Activity

Using these clinical findings of the treatment efficacy of thiamine, we designed an *in vitro* experiment using mouse macrophage RAW264.7 cells to validate the effects of thiamine on alcohol-induced IL-17 and IL-22 expression. The results showed that a low dose of thiamine (V_{B1}) decreased IL-17 expression in the absence (by 20% approximately) and/or presence of alcohol treatment (by 25% roughly) (Figure 2a). Importantly, IL-22 expression was upregulated by thiamine in both the control and ethanol-treated cells. This response in IL-22 expression was moderately reduced by alcohol but rescued by the thiamine (V_{B1}) treatment (Figure 2b). Half of the treatment dose (0.02 $\mu\text{g/mL}$) that was found to be effective in humans was beneficial as a preventative dose (0.01 $\mu\text{g/mL}$) of thiamine in this *in vitro* model.

IL-17 Dependent Dose and Pharmacokinetic Model of Thiamine

An IL-17 response dependent dose and pharmacokinetic model of thiamine administration was developed, based on responses from the pro-inflammatory disease cohorts and the corresponding thiamine dosing (controlled for by the corresponding values in healthy volunteers, as a point of reference). This model supported a tentative range of thiamine dosing for COVID-19 (Figures 3A and 3B), since the IL-17 levels are much higher in COVID-19 than in the reports from many other proinflammatory disease conditions. Using regression analysis, a range of 79 mg/day (lower end of dose range) - 474 mg/day (higher end of dose range) for thiamine administration was found to correspond to a range of 15-40 ng/mL level of IL-17 used *in vitro*.

The pharmacokinetic parameters were: Area Under the Curve (AUC), and Maximum (or peak) Concentration of a drug (C_{max}). These gave a very close estimation of the specific oral thiamine dose (Figure 4). As expected, plasma values were higher for both AUC and C_{max} at higher doses and were lower at lower doses (Suppl Table 2).

Assessment of Neurological Presentation of COVID-19, Viral Encephalitis and Therapeutic Efficacy of Thiamine Administration

We tabulated the neurological symptoms from the recently published findings on COVID-19 (Table 1). Severely ill COVID-19 patients presented with various neurologic symptoms that could be grouped together as: acute cerebrovascular disease; altered mental status; and musculoskeletal symptoms⁵¹. We also included the neurological presentation commonly observed in viral encephalitis of non-COVID-19 origin, grouped corresponding to the presentation of the symptoms of COVID-19.

Lastly, we also tabulated the neurological symptoms that are commonly treated with thiamine. Several neurological symptoms of COVID-19 and viral encephalitis corresponded well with the neurological spectrum that is known to be managed effectively with thiamine.

Discussion

We evaluated individuals with significantly altered IL-17 and IL-22 responses associated with Th17 cells and found a significant role for a 3-week 200 mg/daily thiamine treatment regimen in improving the Th17 response in the AUD disease control patient cohort whose members exhibited a high pro-inflammatory status at baseline. SARS CoV-2 viral challenge

causes induction of IL-6 leading to altered Th17 responses⁵². IL-17 synthesized by Th17 cells can markedly stimulate neutrophil chemotaxis and may lead to a skewed Th2 immune response^{53,54}. Results from our AUD control group show the increases in candidate proinflammatory (IL-1 β and IL-17), and anti-inflammatory (IL-6, IL-10 and IL-22) cytokines. Changes in IL-17 and IL-22 with alcohol abuse (pro-inflammatory), and thiamine as an anti-inflammatory therapy in our experiment provided potential proof of concept. IL-1 β is a key cytokine initiating Th17 cells to synthesize IL-17⁵⁵, whereas IL-10 suppresses Th17 proinflammatory cytokine production⁵⁶. High IL-6 levels also are associated with Th17 cell proinflammatory activity⁵². Thus, under inflammatory conditions, there is a complex interaction of proinflammatory/anti-inflammatory responses from Th17 cells. An intervention or prevention that could attenuate the Th17 proinflammatory activity could help ameliorate the consequences of a cytokine storm.

Thiamine deficiency has been reported to promote a proinflammatory response in Th1 and Th17 cells⁵⁷. To examine the role of thiamine in treating inflammation, *in vitro* testing was used to mechanistically examine the clinical outcomes. Our *in vitro* model showed that thiamine could effectively lower IL-17 and increase IL-22 mRNA expression in macrophages. Both our clinical data, and the *in vitro* studies suggest that thiamine could play a potential role in attenuating the cytokine storm in patients who have a strong proinflammatory response.

A study using a mouse model showed that IL-17 augments respiratory syncytial virus (RSV)-induced lung inflammation⁵⁸. In that study, immunodepletion of IL-17 before viral infection resulted in diminished RSV-driven mucous cell hyperplasia and airspace enlargement, suggesting IL-17 as a potential therapeutic target. Proinflammatory IL-17 production could also initiate pulmonary eosinophilic response, by promoting proliferation of eosinophils in the bone

marrow, followed by recruitment and extravasation into the lungs⁵⁹. These recent findings suggest that suppression of IL-17 may be vital to managing viral infections, including COVID-19 and their harmful consequences.

We derived an effective dose range of thiamine that could be administered for alleviating the Th17 cell proinflammatory response by using the IL-17 concentrations that we obtained from our AUD patients (termed as DC), levels found in the literature, and levels in the healthy control (HV) group. Thiamine has been administered as a treatment in other viral infections^{60,61}, and has proven effective for some inflammatory conditions and symptoms^{62,63}. A well-structured treatment profile of thiamine based on the results of proof of concept *in vitro* experiments, and analyses of proinflammatory response-relevant disease conditions support the potential efficacy of thiamine in ameliorating the proinflammatory Th17 response in severe COVID-19 patients. Use of preventive as well as interventional dosages show potential in the management of COVID-19. Thiamine C_{trough} is reached generally in 10-12 hours; thus, the total dose prescribed can be divided into two doses per day. This may lead to fewer AEs or other side effects.

One recent report identified that 36.4% of the COVID-19 diagnosed patients have neurologic symptoms, and this proportion was higher (45.5%) among those COVID-19 patients with more severe symptoms⁵¹. Patients with other viral diseases have also shown clinical symptoms of beriberi⁶⁴, or Wernicke-Korsakoff syndrome (autopsies of 380 people with AIDS showed Wernicke's encephalopathy in 10% of the cases)⁶⁵, and these conditions are associated with thiamine deficiency. It is possible that patients with viral infection could have an increased risk of thiamine deficiency, but this information has remained largely unexplained in viral

diseases⁶⁶, including COVID-19. A potential reason could be that a deficiency in thiamine could be related to the thiamine transport protein, which can have a general preference for multiple membrane transport molecules which can function as receptors for candidate viruses⁶⁷. The Th17 proinflammatory response has also been reported in the experimental encephalomyelitis model⁵⁷. Thus, thiamine could be a therapeutic agent to alleviate neurological symptoms of COVID-19.

Adverse effects (AE) of thiamine are minimal and generally mild. Possible AEs include nausea, diarrhea, and abdominal pain. Rarely, individuals also suffer serious allergic reactions. There is no reported drug related symptoms at the 200 mg thiamine dose used in our study, and there are no reported AEs. A landmark pharmacokinetic study utilizing a 1500 mg maximum oral dose of thiamine in healthy subjects showed rapid absorption³². Moreover, 4000 mg thiamine administration showed no to mild AEs when used in children (Leigh's disease). Thus, higher doses of thiamine for treatment of COVID-19's cytokine storm could be considered a safe therapy.

Our study has several limitations. This is a small study. However, both clinical and *in vitro* evidence collectively support the potential of thiamine as a therapeutic agent in attenuating the Th17 proinflammatory response. We did not test the *in vitro/in vivo* efficacy of thiamine in the treatment of COVID-19 or its derivative stimulated Th17 proinflammatory response directly. We anticipate conducting such *in vitro* experiments for COVID-19 as a continuation of this project. Moreover, plasma thiamine levels have not been assessed in COVID-19. Our study did not have sufficiently large numbers of males and females; thus, identifying sex-differences was not within the scope of this study.

In summary, Thiamine has been approved by the Food and Drug Administration (FDA) of the USA as a prescription product and is considered very safe even at higher doses since it is water soluble and can be excreted via urine, if in excess⁶⁸. Given its robust safety record, we suggest that thiamine should be considered for COVID-19 treatment studies.

Tables

Table 1. Neurological symptoms in COVID-19, Viral Encephalitis (Grouped/assorted by the neurological spectrum observed in COVID-19), showing their proximity in presentation. Therapeutic effects of thiamine on the corresponding neurological symptoms of pro-inflammatory origin that are also observed in viral infection.

Neurological symptoms			Corresponding Clinical Indications
COVID-19	Viral Encephalitis	Therapeutic Effects of Thiamine on WKS and other Neurological Conditions	
Central Nervous System (CNS) Symptoms			
Altered Mental Status ^{51,69}	Disorientation ⁷⁰	Mental Confusion ^{71,72} , Impaired Memory ⁷¹ ,	Confusion: WKS Classic Triad
Epiphora, Conjunctival Congestion, or Chemosis (swollen conjunctiva) ⁷³ ; Ophthalmoplegia ⁷⁴ (part of MFS)	Ocular Paralysis ⁷⁵ , internuclear Ophthalmoplegia ⁷⁶⁻⁷⁸	Ophthalmoplegia (nystagmus) ⁷¹	Ocular: WKS Classic Triad
Ataxia ^{51,79} (part of MFS): Movement ⁷⁴ , and Unstable Walking ⁶⁹ ,	Ataxia ^{26,70}	Gait Ataxia ⁷¹	Ataxia: WKS Classic Triad
Fatigue ⁶⁹ , Dizziness and Languidness ^{51,69} , Malaise ⁶⁹ , Headache ^{51,69}	Weakness and Somnolence ²⁶ , Nausea ⁸⁰	Lack of Energy/Fatigue, Drowsiness, Fainting, Sluggishness ⁷¹ ; Apathy ⁷¹	Generalized features
Cerebral Hemorrhage ⁶⁹ , Cerebral Infarction ⁶⁹	Cerebral Hemorrhage ⁸¹ , Intracranial Pressure ⁸²	Hemorrhages ⁷¹	Cerebrovascular

Epilepsy ^{51,83}	Epilepsy ^{84,85}	Seizures (Alcohol Withdrawal) ⁸⁶	Pathophysiological
Encephalomyelitis: Demyelinating ^{69,87} , Disseminated ⁸⁸	Encephalomyelitis ^{89,90}	Demyelination ⁹¹ within Periventricular Structures	Pathomorphological
Peripheral Nervous System (PNS) Symptoms			
Hypogeusia (low ability to taste) ^{51,92-94}	Hypogeusia (low ability to taste) ⁹⁵	Efficacy Not Well-Established	Sensory
Hyposmia (low ability to smell) ^{51,93,94,96}	Hyposmia (low ability to smell) ⁹⁵	Efficacy Not Well-Established	Sensory
Nerve pain ⁹⁷ (also in the head and face region ⁵¹)	Neuralgia ^{98,99}	Neuralgia ^{100,101}	Neuralgia
Tachycardia ^{102,103}	Tachycardia ^{70,104}	Racing of Heart (faster heartbeat), Low Blood pressure ⁷¹ , Tachycardia ⁷¹	Cardiovascular
Musculoskeletal Symptoms			
Muscle Injury ^{51,105} Areflexia (part of MFS) ⁷⁴	Dysarthria ²⁶ , Nerve Impairment ¹⁰⁶	Motor impairment ¹⁰⁷ , Motor Cortex Excitability ¹⁰⁸	Motor

Footnote – WKS: Wernicke Korsakoff Syndrome¹⁰⁹; MFS: Miller Fisher Syndrome¹¹⁰.

Figure Legends

Figure 1: Efficacy of thiamine treatment on Th17 cell derived response for IL-17, and IL-22 cytokines. Levels of IL-17 and IL-22 in healthy volunteers (HV) at baseline; and Disease Controls (DC or [alcohol use disorder, AUD]) patients exhibiting a proinflammatory response (n=16) at baseline; and anti-inflammatory normalization of cytokines tested after the completion of three-week (W3) thiamine treatment. A drop in IL-17 coupled with a mild increase in IL-22 at W3 was observed compared to the baseline levels. BL: baseline, W3: three-week of thiamine treatment. Data are presented as M±SD. Statistical significance was set as p < 0.05.

Figure 2: mRNA expression of IL-17 and IL-22 in an *in vitro* model of the mouse macrophage cell line using a potent proinflammatory agent (alcohol), and preventative administration of thiamine. Fig. 2a: Significant lowering was observed in IL-17 mRNA expression in “EtOH + V_{B1}” (Bar 4) group compared to the alcohol-treated group (Bar 3). Fig. 2b: Significant elevation was observed in IL-22 mRNA expression in “EtOH + V_{B1}” (Bar 4) group compared to the alcohol-treated group (Bar 3). Controls (both Fig. 2a and 2b) show normal anti-inflammatory effects of thiamine on IL-17 and IL-22 response with thiamine administration. Ctrl: Non-treated controls. V_{B1} 0.01 ug/ml. EtOH: alcohol treated. V_{B1}+E: thiamine and alcohol treated. Data are presented as M±SD. Statistical significance was set as $p < 0.05$.

Figure 3. PRIMARY: A dose titration by disease and proinflammatory Th17 status model of thiamine administration with parallel representation of Th17 proinflammatory response in various groups including healthy volunteers and disease groups with pro-inflammatory response. Fig. 3A: Linear regression model is predictive for the relation between the low dose thiamine (Vit B1) range versus low IL-17 ranges based on known observed pairs from different patients; lower range of vit B1 dose (79 mg/daily) corresponding to lower range of IL-17 (15 ng/ml) in the COVID-19 patients. Dark grey shade depicts higher IL-17 response and lighter grey shade shows lower IL-17 response in various proinflammatory conditions. Fig. 3B: Linear regression shows the predictive model for the relation between a higher range of Vit B1 dose versus a higher range of IL-17 levels, derived from the known observed pairs from different patients; higher range of Vit B1 dose (474 mg/daily) corresponding to higher range of IL-17 (40 ng/ml) reported in COVID-19 patients. High Range Thiamine Dose: Left Y-axis (primary). Low

Range Thiamine Dose, Low Range IL-17 levels, and High range IL-17 levels: Right Y-axis
(Secondary).

Figure. 4. Pharmacokinetics parameters of oral thiamine over 10 hr. (Projected) in whole blood and plasma. Fig. 4a: Predicted course of Area Under the Curve (AUC) for low values (79 mg/day) and high values (474 mg/day) of the range of oral thiamine dose in blood and plasma over the 10 hours. Fig. 4b: Predicted maximum concentration of low values (79 mg/day) and high values (474 mg/day) of the range of oral thiamine dose in blood and plasma over the first 10 hours. Errors bars show a 5% variability in the pharmacokinetic measures at each dose.

References

1. Hassell JM, Begon M, Ward MJ, Fèvre EM. Urbanization and disease emergence: dynamics at the wildlife–livestock–human interface. *Trends in ecology & evolution*. 2017;32(1):55-67.
2. Poon LL, Peiris M. Emergence of a novel human coronavirus threatening human health. *Nature medicine*. 2020;26(3):317-319.
3. HuiDS IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis*. 2020;91:264-266.
4. Glass WG, Rosenberg HF, Murphy PM. Chemokine regulation of inflammation during acute viral infection. *Current opinion in allergy and clinical immunology*. 2003;3(6):467-473.
5. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. *Nature Reviews Immunology*. 2020:1-12.
6. Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. *The Journal of clinical investigation*. 2020;130(5).
7. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet*. 2020;395(10229):1033-1034.

8. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. *Journal of leukocyte biology*. 2002;71(1):1-8.
9. Reed M, Morris SH, Owczarczyk AB, Lukacs NW. Deficiency of autophagy protein Map1-LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER stress-associated IL-1. *Mucosal immunology*. 2015;8(5):1118-1130.
10. Jain A, Pandey N, Garg R, Kumar R. IL-17 level in patients with Dengue virus infection & its association with severity of illness. *Journal of clinical immunology*. 2013;33(3):613-618.
11. Yuan J, Yu M, Lin Q-W, et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. *International immunopharmacology*. 2010;10(3):272-276.
12. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. *The American journal of pathology*. 2011;179(1):248-258.
13. Du W-J, Zhen J-H, Zeng Z-Q, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. *Diagnostic pathology*. 2013;8(1):40.
14. Li C, Yang P, Sun Y, et al. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. *Cell research*. 2012;22(3):528-538.
15. Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. *Mucosal immunology*. 2012;5(6):646-657.
16. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. *Brain, behavior, and immunity*. 2020.
17. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and pathology. *European journal of immunology*. 2017;47(4):607-614.
18. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? *Nature Reviews Immunology*. 2020;20(6):345-346.
19. Cooper JR, Pincus JH. The role of thiamine in nervous tissue. *Neurochemical research*. 1979;4(2):223-239.
20. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. *Current diabetes reviews*. 2005;1(3):287-298.
21. Neri M, Cantatore S, Pomara C, et al. Immunohistochemical expression of proinflammatory cytokines IL-1 β , IL-6, TNF- α and involvement of COX-2, quantitatively confirmed by Western blot analysis, in Wernicke's encephalopathy. *Pathology-Research and Practice*. 2011;207(10):652-658.
22. de Andrade JAA, Gayer CRM, de Almeida Nogueira NP, et al. The effect of thiamine deficiency on inflammation, oxidative stress and cellular migration in an experimental model of sepsis. *Journal of Inflammation*. 2014;11(1):11.
23. Menezes RR, Godin AM, Rodrigues FF, et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. *Pharmacological Reports*. 2017;69(5):1036-1043.

24. Shahmiri FA, Soares M, Zhao Y, Sherriff J. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial. *European journal of nutrition*. 2013;52(7):1821-1824.
25. Protheroe S, Mellor D. Imaging in influenza A encephalitis. *Archives of disease in childhood*. 1991;66(6):702-705.
26. Brechtelsbauer D, Urbach H, Sommer T, Blümcke I, Woitas R, Solymosi L. Cytomegalovirus encephalitis and primary cerebral lymphoma mimicking Wernicke's encephalopathy. *Neuroradiology*. 1997;39(1):19-22.
27. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. *Alcohol and Alcoholism*. 2000;35(Supplement_1):2-1.
28. Vatsalya V, Song M, Schwandt ML, et al. Effects of sex, drinking history, and omega-3 and omega-6 fatty acids dysregulation on the onset of liver injury in very heavy drinking alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research*. 2016;40(10):2085-2093.
29. Vatsalya V, Kong M, Cave MC, et al. Association of serum zinc with markers of liver injury in very heavy drinking alcohol-dependent patients. *The Journal of nutritional biochemistry*. 2018;59:49-55.
30. Vatsalya V, Agrawal R, Frimodig J, Srivastava S, Schwandt ML. Dysregulation in Plasma ω 3 Fatty Acids Concentration and Serum Zinc in Heavy Alcohol-Drinking HCV Patients. *Advances in Virology*. 2020;2020.
31. Vatsalya V, Cave MC, Kong M, et al. Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis. *Clinical Gastroenterology and Hepatology*. 2019.
32. Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. *BMC clinical pharmacology*. 2012;12(1):4.
33. Mandel H, Berant M, Hazani A, Naveh Y. Thiamine-dependent beriberi in the thiamine-responsive anemia syndrome. *New England Journal of Medicine*. 1984;311(13):836-838.
34. Riaz S, Skinner V, Srai SK. Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2. *Journal of pharmaceutical and biomedical analysis*. 2011;54(4):817-825.
35. Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial. *Ann Am Thorac Soc*. 2017;14(5):737-741.
36. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. *Chest*. 2017;151(6):1229-1238.
37. Mouly S. Beri-Beri and thiamine deficiency in HIV infection. *Aids*. 1996;10(8):931.
38. Arici C, Tebaldi A, Quinzan G, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. *International journal of STD & AIDS*. 2001;12(6):407-409.
39. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. *Journal of Medical Toxicology*. 2014;10(1):26-39.

40. Di Rocco M, Lamba LD, Minniti G, Caruso U, Naito E. Outcome of thiamine treatment in a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase deficiency. *European Journal of Paediatric Neurology*. 2000;4(3):115-117.
41. Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. *Cochrane Database of Systematic Reviews*. 2013(7).
42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
43. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. *Journal of Microbiology, Immunology and Infection*. 2020.
44. Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. *National Science Review*. 2020.
45. Pirowska M, Obtulowicz A, Lipko-Godlewska S, Goździalska A, Podolec K, Wojas-Pelc A. The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. *Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii*. 2018;35(4):360.
46. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. *The Journal of clinical investigation*. 1999;103(9):1345-1352.
47. Brunialti MKC, Santos MC, Rigato O, Machado FR, Silva E, Salomao R. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. *PloS one*. 2012;7(5):e37393.
48. Li J, Li M, Su L, et al. Alterations of T helper lymphocyte subpopulations in sepsis, severe sepsis, and septic shock: a prospective observational study. *Inflammation*. 2015;38(3):995-1002.
49. Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of influenza infection. *The Journal of Immunology*. 2009;183(8):5301-5310.
50. Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. *Clinical and Developmental Immunology*. 2013;2013.
51. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. 2020.
52. Hotez PJ, Bottazzi ME, Corry DB. The potential role of TH17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. In: Elsevier; 2020.
53. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. *Cell Signal*. 2013;25(12):2335-2347.
54. Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. *Nat Immunol*. 2017;18(6):612-621.
55. Lasiglie D, Traggiai E, Federici S, et al. Role of IL-1 Beta in the Development of Human TH 17 Cells: Lesson from NLPR3 Mutated Patients. *PloS one*. 2011;6(5):e20014.
56. Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. *European journal of immunology*. 2008;38(7):1807-1813.

57. Ji Z, Fan Z, Zhang Y, et al. Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. *The Journal of Immunology*. 2014;193(5):2157-2167.
58. Mebratu YA, Tesfaigzi Y. IL-17 Plays a Role in Respiratory Syncytial Virus-induced Lung Inflammation and Emphysema in Elastase and LPS-injured Mice. *Am J Respir Cell Mol Biol*. 2018;58(6):717-726.
59. Murdock BJ, Falkowski NR, Shreiner AB, et al. Interleukin-17 drives pulmonary eosinophilia following repeated exposure to *Aspergillus fumigatus* conidia. *Infection and immunity*. 2012;80(4):1424-1436.
60. Shoji S, Furuishi K, Misumi S, Miyazaki T, Kino M, Yamataka K. Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production. *Biochemical and biophysical research communications*. 1994;205(1):967-975.
61. Butterworth RF, Gaudreau C, Vincelette J, Bourgault A-M, Lamothe F, Nutini A-M. Thiamine deficiency and Wernicke's encephalopathy in AIDS. *Metabolic brain disease*. 1991;6(4):207-212.
62. Wallace AE, Weeks WB. Thiamine treatment of chronic hepatitis B infection. *The American journal of gastroenterology*. 2001;96(3):864-868.
63. Kim W-Y, Jo E-J, Eom JS, et al. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. *Journal of critical care*. 2018;47:211-218.
64. Coates PM, Betz JM, Blackman MR, et al. *Encyclopedia of dietary supplements*. CRC Press; 2010.
65. Boldorini R, Vago L, Lechi A, Tedeschi F, Trabattoni G. Wernicke's encephalopathy: occurrence and pathological aspects in a series of 400 AIDS patients. *Acta Bio-medica de L'ateneo Parmense: Organo Della Societa di Medicina e Scienze Naturali di Parma*. 1992;63(1-2):43-49.
66. Larsen TR, Dragu D, Williams M. Wernicke's encephalopathy: an unusual consequence of the acquired immune deficiency syndrome—case report and literature review. *Case reports in medicine*. 2013;2013.
67. Mendoza R, Anderson MM, Overbaugh J. A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. *Journal of Virology*. 2006;80(7):3378-3385.
68. Plaut G. Water-soluble vitamins, part II (folic acid, riboflavin, thiamine, vitamin B12). *Annual Review of Biochemistry*. 1961;30(1):409-444.
69. Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W. Potential neurological symptoms of COVID-19. *Therapeutic Advances in Neurological Disorders*. 2020;13:1756286420917830.
70. Chaudhuri A, Kennedy P. Diagnosis and treatment of viral encephalitis. *Postgraduate medical journal*. 2002;78(924):575-583.
71. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. *The Lancet Neurology*. 2007;6(5):442-455.
72. Reuler JB, Girard DE, Cooney TG. Wernicke's encephalopathy. *New England Journal of Medicine*. 1985;312(16):1035-1039.

73. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. *JAMA ophthalmology*. 2020;138(5):575-578.
74. Lantos J, Strauss S, Lin E. COVID-19—Associated Miller Fisher Syndrome: MRI Findings. *American Journal of Neuroradiology*. 2020.
75. Keane JR. Bilateral ocular paralysis: analysis of 31 inpatients. *Archives of neurology*. 2007;64(2):178-180.
76. Keane JR. Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. *Archives of neurology*. 2005;62(5):714-717.
77. Hedges III TR. Ophthalmoplegia associated with AIDS. *Survey of ophthalmology*. 1994;39(1):43-51.
78. Sanjay S, Chan EWe, Gopal L, Hegde SR, Chang BC-M. Complete unilateral ophthalmoplegia in herpes zoster ophthalmicus. *Journal of Neuro-ophthalmology*. 2009;29(4):325-337.
79. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. *Pediatrics*. 2004;113(1):e73-e76.
80. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. *The Lancet*. 2002;359(9305):507-513.
81. Kabakus N, Gurgoze MK, Yildirim H, Godekmerdan A, Aydin M. Acute hemorrhagic leukoencephalitis manifesting as intracerebral hemorrhage associated with herpes simplex virus type I. *Journal of tropical pediatrics*. 2005;51(4):245-249.
82. Kumar G, Kalita J, Misra UK. Raised intracranial pressure in acute viral encephalitis. *Clinical neurology and neurosurgery*. 2009;111(5):399-406.
83. Hao X, Zhou D, Li Z, et al. Severe psychological distress among patients with epilepsy during the COVID-19 outbreak in southwest China. *Epilepsia*. 2020.
84. Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. *Epilepsia*. 2008;49:13-18.
85. AGUILAR MJ, RASMUSSEN T. Role of encephalitis in pathogenesis of epilepsy. *AMA Archives of Neurology*. 1960;2(6):663-676.
86. Nguyen TA, Lam SW. Phenobarbital and symptom-triggered lorazepam versus lorazepam alone for severe alcohol withdrawal in the intensive care unit. *Alcohol*. 2020;82:23-27.
87. Steardo L, Steardo Jr L, Zorec R, Verkhatsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. *Acta Physiologica*. 2020:e13473.
88. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. *Acta Neuropathologica*. 2020:1-6.
89. Dale RC. Acute disseminated encephalomyelitis. Paper presented at: Seminars in pediatric infectious diseases2003.
90. Whitley RJ. Viral encephalitis. *New England Journal of Medicine*. 1990;323(4):242-250.
91. Rao R, Topiwala A. Alcohol use disorders and the brain. *Addiction*. 2020.
92. Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. *Obesity*. 2020;28(5):848-848.

93. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *European Archives of Oto-Rhino-Laryngology*. 2020;1-11.
94. Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients. *Journal of Medical Virology*. 2020.
95. Henkin R, Larson A, Powell R. Hypogeusia, dysgeusia, hyposmia, and dysosmia following influenza-like infection. *Annals of Otology, Rhinology & Laryngology*. 1975;84(5):672-682.
96. Bénézit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. *The Lancet Infectious Diseases*. 2020.
97. Azhideh A. COVID-19 Neurological Manifestations. *International Clinical Neuroscience Journal*. 2020;7(2):54.
98. Tang H, Falcone F, Eljamel S. Herpes simplex encephalitis following microvascular decompression for trigeminal neuralgia: Case report. *Journal of Neurosurgery*. 2013;118(3):530-533.
99. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. *BMC medicine*. 2010;8(1):37.
100. Rose AS, Jacobson BM. Treatment of trigeminal neuralgia with vitamin B1 (thiamine hydrochloride). *Archives of Neurology & Psychiatry*. 1940;44(6):1307-1311.
101. Eckert M, Schejbal P. Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful diseases of the peripheral nervous system with a combination preparation of thiamine, pyridoxine and cyanocobalamin. *Fortschritte der Medizin*. 1992;110(29):544-548.
102. He J, Wu B, Chen Y, et al. Characteristic ECG manifestations in patients with COVID-19. *Canadian Journal of Cardiology*. 2020.
103. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. *Journal of Cardiovascular Electrophysiology*. 2020;31(5):1003-1008.
104. Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. *The Lancet*. 1999;354(9186):1257-1259.
105. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). In: *Statpearls [internet]*. StatPearls Publishing; 2020.
106. Ripamonti E, Gaffuri M, Molteni F. Cognitive, neuropsychiatric, and motor profile in post tick-borne flaviviral encephalomyelitis. *Neurological Sciences*. 2020.
107. Pitel A-L, Zahr NM, Jackson K, et al. Signs of preclinical Wernicke's encephalopathy and thiamine levels as predictors of neuropsychological deficits in alcoholism without Korsakoff's syndrome. *Neuropsychopharmacology*. 2011;36(3):580-588.
108. Nardone R, Bergmann J, Kronbichler M, et al. Altered motor cortex excitability to magnetic stimulation in alcohol withdrawal syndrome. *Alcoholism: clinical and experimental research*. 2010;34(4):628-632.

- 741 109. Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with
742 Wernicke-Korsakoff syndrome. *New England Journal of Medicine*. 1977;297(25):1367-
743 1370.
- 744 110. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of
745 Miller Fisher syndrome. *Neurology*. 2001;56(8):1104-1106.
746

Figure 1

Fig. 1a

Fig. 1b

Figure 2

Fig. 2a

Fig. 2b

Figure 3

Figure 4

Fig. 4a

Fig. 4b